Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb)

被引:7
作者
Azari, M
Boose, JA
Burhop, KE
Camacho, T
Catarello, J
Darling, A
Ebeling, AA
Estep, TN
Pearson, L
Guzder, S
Herren, J
Ogle, K
Paine, J
Rohn, K
Sarajari, R
Sun, CS
Zhang, L
机构
[1] Baxter Healthcare Corp, Hemoglobin Therapeut Program, Round Lake, IL 60073 USA
[2] Baxter Healthcare Corp, Biomed Resources Virol Lab, Round Lake, IL 60073 USA
[3] BioReliance Inc, Rockville, MD 20850 USA
关键词
diaspirin crosslinked haemoglobin (DCLHb); haemoglobin therapeutic; ultrafiltration; virus removal;
D O I
10.1006/biol.2000.0246
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Virus retention during ultrafiltration through A/G Technology filter cartridges was investigated to characterize the removal process and validate the degree of virus titre reduction during the filtration of red blood cell haemolysates performed as part of the production of diaspirin crosslinked haemoglobin (DCLHb). When viruses were suspended in phosphate buffered saline solution, retention was greater with larger sized viruses and smaller filter pore size. Virus titre was maintained at starting levels in the filter retentate circuit during the course of filtration, suggesting that the virus removal mechanism is predominantly size exclusion. Evaluation of specific processing variables indicated that the retention of phi X174 virus was increased in the presence of red blood cell haemolysate or at high membrane crossflow rates and transmembrane pressures, while the retention of EMC virus was less sensitive to variations in these parameters. Using these results to design a validation protocol, log reduction values of >7.9 were demonstrated for the retention of human immunodeficiency virus, pseudorabies virus and bovine viral diarrhoea viruses, 7.6 for hepatitis A virus, and 4.2 for porcine parvovirus. It was also shown that the retention of viruses was maintained during repetitive use of the same filter cartridge. (C) 2000 The International Association for Biologicals.
引用
收藏
页码:81 / 94
页数:14
相关论文
共 11 条
[1]  
*AG TECHN CORP, 1997, VIR RET MEMBR VAL 10
[2]   Validation of the heat treatment step used in the production of diaspirin crosslinked hemoglobin (DCLHb™) for viral inactivation [J].
Azari, M ;
Ebeling, A ;
Baker, R ;
Burhop, K ;
Camacho, T ;
Estep, T ;
Guzder, S ;
Marshall, T ;
Rohn, K ;
Sarajari, R ;
Boose, JA ;
Gauvin, G ;
Horner, R ;
Lu, B ;
Pearson, L ;
Vacante, D .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1998, 26 (5-6) :577-582
[3]   NANOFILTRATION, A NEW SPECIFIC VIRUS ELIMINATION METHOD APPLIED TO HIGH-PURITY FACTOR-IX AND FACTOR-XI CONCENTRATES [J].
BURNOUFRADOSEVICH, M ;
APPOURCHAUX, P ;
HUART, JJ ;
BURNOUF, T .
VOX SANGUINIS, 1994, 67 (02) :132-138
[4]  
CHARTTERJEE R, 1986, J BIOL CHEM, V261, P9929
[5]   SIZE-EXCLUSION REMOVAL OF MODEL MAMMALIAN VIRUSES USING A UNIQUE MEMBRANE SYSTEM .2. MODULE QUALIFICATION AND PROCESS SIMULATION [J].
DILEO, AJ ;
VACANTE, DA ;
DEANE, EF .
BIOLOGICALS, 1993, 21 (03) :287-296
[6]  
HO WSW, 1992, MEMBRANE HDB
[7]  
JACANGELO JG, 1995, APPL MEMBRANE FILTRA
[8]   THEORETICAL-ANALYSIS OF PORE-SIZE DISTRIBUTION EFFECTS ON MEMBRANE-TRANSPORT [J].
MOCHIZUKI, S ;
ZYDNEY, AL .
JOURNAL OF MEMBRANE SCIENCE, 1993, 82 (03) :211-227
[9]   PREPARATION AND CHARACTERIZATION OF DIASPIRIN CROSS-LINKED HEMOGLOBIN-SOLUTIONS FOR PRECLINICAL STUDIES [J].
NELSON, D ;
AZARI, M ;
BROWN, R ;
BURHOP, K ;
BUSH, S ;
CATARELLO, J ;
CHUANG, H ;
DOWNING, C ;
ESTEP, T ;
LOEWEN, A ;
MCCLURE, K ;
MCDANIEL, A ;
MICHALEK, E ;
MOZIER, N ;
ROHN, K ;
SPICUZZA, J ;
ZIESKE, P ;
ZIMMERMAN, G .
BIOMATERIALS ARTIFICIAL CELLS AND IMMOBILIZATION BIOTECHNOLOGY, 1992, 20 (2-4) :423-427
[10]   The risk of transfusion-transmitted viral infections [J].
Schreiber, GB ;
Busch, MP ;
Kleinman, SH ;
Korelitz, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1685-1690